MDMA-assisted therapy for PTSD has been a topic of intense research and debate in recent years. Initial research on MDMA for PTSD began in the early 2000s, with promising results from small-scale trials. Between 2004 and 2017, six Phase 2 trials were conducted, showing significant reductions in PTSD symptoms among participants receiving MDMA-assisted therapy. Two Phase 3 trials, completed in 2021 and 2022, demonstrated that 67-71% of participants experienced post-traumatic growth, no longer met PTSD diagnostic criteria after three MDMA-assisted therapy sessions, compared to 32-48% in the placebo groups. Then, an observational follow-up study suggested that the treatment’s effects may last for at least six months.
Here’s a list of major studies on MDMA for PTSD and their key findings:
- MAPS Phase 2 Trials (2004-2017):
Six Phase 2 trials were conducted, showing significant reductions in PTSD symptoms among participants receiving MDMA-assisted therapy.- MAPS Phase 3 MAPP1 Trial (2021):
This randomized, double-blind, placebo-controlled study found that 67% of participants who received MDMA-assisted therapy no longer met PTSD diagnostic criteria after three sessions, compared to 32% in the placebo group.- MAPS Phase 3 MAPP2 Trial (2023):
This confirmatory study replicated the MAPP1 results, with 71.2% of participants no longer meeting PTSD criteria after MDMA-assisted therapy. The study also demonstrated efficacy across a diverse population, including those with comorbidities.- Long-term follow-up study (2023):
An observational study suggested that the treatment effects of MDMA-assisted therapy for PTSD may last for at least six months.- MPLONG safety studies:
Multiple ongoing studies have shown that MDMA has been administered to approximately 1,700 human subjects with only one serious adverse reaction reported.
- Forums
- ASX - By Stock
- EMD
- FDA
EMD
emyria limited
Add to My Watchlist
0.00%
!
2.7¢

FDA, page-4
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
2.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.50M |
Open | High | Low | Value | Volume |
2.7¢ | 2.7¢ | 2.7¢ | $10.27K | 380.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 347026 | 2.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.7¢ | 103182 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 289334 | 0.026 |
3 | 540000 | 0.025 |
7 | 1004393 | 0.024 |
10 | 943478 | 0.023 |
4 | 508381 | 0.022 |
Price($) | Vol. | No. |
---|---|---|
0.027 | 103182 | 1 |
0.028 | 816958 | 3 |
0.029 | 1236393 | 6 |
0.030 | 157104 | 3 |
0.031 | 94812 | 1 |
Last trade - 15.58pm 08/07/2025 (20 minute delay) ? |
Featured News
EMD (ASX) Chart |